Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK) announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE